Suchergebnisse - "Balar, Arjun V"

PubPharm (7)

1

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer : Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Bellmunt, J. | de Wit, R. | Fradet, Y. | +28

CommentIn: J Urol. 2023 May;209(5):1025-1026. - PMID 37026649

2

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057) : an open-label, single-arm, multicentre, phase 2 study

enthalten in: The Lancet. Oncology | 2021

von Balar, A. | Kamat, A. | Kulkarni, G. | +15

CommentIn: Nat Rev Urol. 2021 Oct;18(10):577-578. - PMID 34230659

3

Long-Term Outcomes in KEYNOTE-052 : Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Vuky, J. | Balar, A. | Castellano, D. | +13

4

Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer : A Single Institution Experience

enthalten in: Clinical genitourinary cancer | 2020

von Hsu, M. | Xia, Y. | Troxel, A. | +5

5

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052) : Outcomes in Older Patients by Age and Performance Status

enthalten in: European urology oncology | 2020

von Grivas, P. | Plimack, E. | Balar, A. | +11

6

Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma

enthalten in: Oncology (Williston Park, N.Y.) | 2019

von Balar, A.

7

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052) : a multicentre, single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2017

von Balar, A. | Castellano, D. | O'Donnell, P. | +12

CommentIn: Lancet Oncol. 2017 Nov;18(11):1428-1430. - PMID 28967486

1
[1]